Genmab 향후 성장

Future 기준 점검 4/6

Genmab (는) 각각 연간 9% 및 10.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 32.3% 로 예상됩니다.

핵심 정보

9.0%

이익 성장률

7.66%

EPS 성장률

Biotechs 이익 성장	21.5%
매출 성장률	10.3%
향후 자기자본이익률	32.30%
애널리스트 커버리지	Good
마지막 업데이트	06 Jan 2026

최근 향후 성장 업데이트

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 11

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Feb 17

Recent updates

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Sep 24

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

Jul 31

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 11

It's Unlikely That The CEO Of Genmab A/S (CPH:GMAB) Will See A Huge Pay Rise This Year

Mar 06

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Feb 17

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Nov 11 Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.

이익 및 매출 성장 예측

CPSE:GMAB - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	5,818	1,981	2,820	2,413	7
12/31/2027	5,000	1,431	1,766	1,227	12
12/31/2026	4,288	989	1,397	920	13
12/31/2025	3,710	1,170	961	917	15
9/30/2025	3,846	1,583	1,294	1,369	N/A
6/30/2025	3,647	1,371	1,055	1,134	N/A
3/31/2025	3,231	1,140	1,124	1,194	N/A
12/31/2024	2,990	1,090	1,037	1,079	N/A
9/30/2024	2,964	702	980	1,005	N/A
6/30/2024	2,743	798	939	971	N/A
3/31/2024	2,576	791	775	818	N/A
12/31/2023	2,440	645	1,037	1,093	N/A
9/30/2023	2,389	590	806	866	N/A
6/30/2023	2,378	680	826	885	N/A
3/31/2023	2,216	757	902	955	N/A
12/31/2022	2,088	785	518	563	N/A
9/30/2022	1,580	745	459	495	N/A
6/30/2022	1,438	558	277	315	N/A
3/31/2022	1,342	354	201	242	N/A
12/31/2021	1,288	452	302	341	N/A
9/30/2021	1,232	448	148	185	N/A
6/30/2021	1,168	401	894	928	N/A
3/31/2021	1,703	880	856	899	N/A
12/31/2020	1,660	781	1,006	1,056	N/A
9/30/2020	1,736	889	1,122	1,166	N/A
6/30/2020	1,559	853	357	399	N/A
3/31/2020	837	349	361	383	N/A
12/31/2019	806	325	182	199	N/A
9/30/2019	532	223	183	198	N/A
6/30/2019	487	178	N/A	190	N/A
3/31/2019	441	202	N/A	180	N/A
12/31/2018	464	226	N/A	156	N/A
9/30/2018	437	222	N/A	165	N/A
6/30/2018	397	194	N/A	140	N/A
3/31/2018	462	213	N/A	215	N/A
12/31/2017	381	178	N/A	256	N/A
9/30/2017	361	184	N/A	200	N/A
6/30/2017	356	208	N/A	218	N/A
3/31/2017	272	174	N/A	156	N/A
12/31/2016	257	168	N/A	46	N/A
9/30/2016	221	111	N/A	99	N/A
6/30/2016	205	102	N/A	88	N/A
3/31/2016	183	82	N/A	55	N/A
12/31/2015	165	111	N/A	45	N/A
9/30/2015	116	66	N/A	10	N/A
6/30/2015	115	69	N/A	3	N/A
3/31/2015	102	60	N/A	14	N/A

애널리스트 향후 성장 전망

수입 대 저축률: GMAB 의 연간 예상 수익 증가율(9%)이 saving rate(1.7%)보다 높습니다.

수익 vs 시장: GMAB 의 연간 수익(9%)이 Danish 시장(6.1%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: GMAB 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: GMAB 의 수익(연간 10.3%)이 Danish 시장(연간 4.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: GMAB 의 수익(연간 10.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: GMAB의 자본 수익률은 3년 후 32.3%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/06 01:49
종가	2026/01/06 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Genmab A/S는 44명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Xue Chen	Barclays
Emily Field	Barclays
Xian Deng	Berenberg

Genmab 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Genmab Provides Earnings Guidance for the Full Year 2025

Consensus EPS estimates increase by 10%, revenue downgraded

Genmab A/S Raises Earnings Guidance for the Year 2025

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Consensus EPS estimates increase by 16%

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Recent updates

Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Senior Director recently sold kr.343k worth of stock

Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S to Report First Half, 2026 Results on Aug 06, 2026

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Genmab Provides Earnings Guidance for the Full Year 2025

Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Investor sentiment improves as stock rises 16%

Genmab Reportedly in Advanced Talks to Buy Merus

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Co-Founder exercised options to buy kr.42m worth of stock.

Genmab A/S Announces Updated Results from Phase 2 Epcore®? Nhl-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 10%, revenue downgraded

Genmab A/S Raises Earnings Guidance for the Year 2025

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

Genmab Announces Changes to Its Executive Committee

Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial

Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association (Eha) Congress

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma

Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer

Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-S

Investor sentiment deteriorates as stock falls 16%

It's Unlikely That The CEO Of Genmab A/S (CPH:GMAB) Will See A Huge Pay Rise This Year

Consensus EPS estimates increase by 16%

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Genmab A/S, Annual General Meeting, Mar 12, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Provides Revenue Guidance for 2025

Insufficient new directors

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%